These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 15685830)

  • 21. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
    Gilbert J; Cmelak A; Shyr Y; Netterville J; Burkey BB; Sinard RJ; Yarbrough WG; Chung CH; Aulino JM; Murphy BA
    Cancer; 2008 Jul; 113(1):186-92. PubMed ID: 18484593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
    Janjigian YY; Ku GY; Campbell JC; Shah MA; Capanu M; Kelsen DP; Ilson DH
    Am J Clin Oncol; 2014 Apr; 37(2):126-30. PubMed ID: 23211227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Enzinger PC; Burtness BA; Niedzwiecki D; Ye X; Douglas K; Ilson DH; Villaflor VM; Cohen SJ; Mayer RJ; Venook A; Benson AB; Goldberg RM
    J Clin Oncol; 2016 Aug; 34(23):2736-42. PubMed ID: 27382098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
    Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
    BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
    Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
    Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
    Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
    J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
    Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
    Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):75-82. PubMed ID: 20198372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
    Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Earle CC; Kulke MH; Meyerhardt JA; Blaszkowsky LS; Zhu AX; Fidias P; Vincitore MM; Mayer RJ; Fuchs CS
    Ann Oncol; 2009 Mar; 20(3):475-80. PubMed ID: 19139178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
    Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
    Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
    Shen WC; Yang TS; Hsu HC; Chen JS
    Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.